Next Article in Journal
Automated Fiber Diameter and Porosity Measurements of Plasma Clots in Scanning Electron Microscopy Images
Next Article in Special Issue
Cardiorenal Syndrome: New Pathways and Novel Biomarkers
Previous Article in Journal
CRMP2 as a Candidate Target to Interfere with Lung Cancer Cell Migration
Previous Article in Special Issue
Native Low-Density Lipoproteins Act in Synergy with Lipopolysaccharide to Alter the Balance of Human Monocyte Subsets and Their Ability to Produce IL-1 Beta, CCR2, and CX3CR1 In Vitro and In Vivo: Implications in Atherogenesis
Article

Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology

1
Division of Rheumatology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary
2
Division of Metabolic Diseases, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary
3
Department of Sports Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary
4
Intensive Care Unit, Department of Medicine, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary
5
Department of Oncology, Faculty of Medicine, University of Debrecen, 4031 Debrecen, Hungary
*
Author to whom correspondence should be addressed.
Shared first authorship with equal contribution.
Shared last authorship with equal contribution.
Academic Editors: Roberto Scicali, Alessandro Mattina and Giuseppe Mandraffino
Biomolecules 2021, 11(10), 1535; https://doi.org/10.3390/biom11101535
Received: 26 July 2021 / Revised: 15 October 2021 / Accepted: 15 October 2021 / Published: 18 October 2021
Background: Cardiovascular (CV) morbidity, mortality, and metabolic syndrome are associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Here, lipids and other metabolic markers in relation to vascular function and clinical markers were evaluated in RA and AS patients undergoing one-year anti-TNF therapy. Patients and methods: Fifty-three patients including 36 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 17 AS patients treated with ETN were included in a 12-month follow-up study. Various lipids, paraoxonase (PON) and arylesterase (ARE) activities, myeloperoxidase (MPO) and adipokine levels were determined overtime. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV) in all patients. All assessments were performed at baseline and 6 and 12 months after treatment initiation. Results: Anti-TNF therapy decreased ARE activity, MPO, adiponectin, and chemerin levels after 12 months (p < 0.05). Lipids, PON activity, and leptin remained unchanged. Regression analyses suggested variable associations of IMT, PWV, and FMD with ARE, MPO, leptin, and lipids (p < 0.05). On the other hand, these metabolic parameters were significantly associated with disease duration, CV history, CRP, obesity, PWV, and IMT (p < 0.05). One-year anti-TNF treatment together with baseline leptin (p = 0.039) or CRP (p = 0.016) levels determined 12 months of lipid changes overtime. TNF inhibition together with baseline disease activity determined ARE activity changes (p = 0.046). Anti-TNF therapy and baseline chemerin levels determined IMT changes overtime (p = 0.003). Conclusions: Assessment of various metabolic parameters together with disease activity, CRP, and ultrasound-based techniques may exert additional value in determining CV burden and in monitoring the effects of biologics on preclinical vascular pathophysiology. View Full-Text
Keywords: rheumatoid arthritis; ankylosing spondylitis; biologic therapy; metabolic biomarkers; lipids; adipokines rheumatoid arthritis; ankylosing spondylitis; biologic therapy; metabolic biomarkers; lipids; adipokines
Show Figures

Figure 1

MDPI and ACS Style

Czókolyová, M.; Pusztai, A.; Végh, E.; Horváth, Á.; Szentpéteri, A.; Hamar, A.; Szamosi, S.; Hodosi, K.; Domján, A.; Szántó, S.; Kerekes, G.; Seres, I.; Harangi, M.; Paragh, G.; Szekanecz, É.; Szekanecz, Z.; Szűcs, G. Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology. Biomolecules 2021, 11, 1535. https://doi.org/10.3390/biom11101535

AMA Style

Czókolyová M, Pusztai A, Végh E, Horváth Á, Szentpéteri A, Hamar A, Szamosi S, Hodosi K, Domján A, Szántó S, Kerekes G, Seres I, Harangi M, Paragh G, Szekanecz É, Szekanecz Z, Szűcs G. Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology. Biomolecules. 2021; 11(10):1535. https://doi.org/10.3390/biom11101535

Chicago/Turabian Style

Czókolyová, Monika, Anita Pusztai, Edit Végh, Ágnes Horváth, Anita Szentpéteri, Attila Hamar, Szilvia Szamosi, Katalin Hodosi, Andrea Domján, Sándor Szántó, György Kerekes, Ildikó Seres, Mariann Harangi, György Paragh, Éva Szekanecz, Zoltán Szekanecz, and Gabriella Szűcs. 2021. "Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology" Biomolecules 11, no. 10: 1535. https://doi.org/10.3390/biom11101535

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop